Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease

Journal of Neuroscience Research

Volumn 89, Issue 11, 2011, Pages 1812-1821

  Rockenstein, Edward ^a   Ubhi, Kiren ^a   Pham, Emiley ^a   Michael, Sarah ^a   Doppler, Edith ^b   Novak, Philipp ^b   Inglis, Chandra ^a   Mante, Michael ^a   Adame, Anthony ^a   Alvarez, X Anton ^c   Moessler, Herbert ^b   Masliah, Eliezer ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EVER Neuro Pharma   (Austria)

^c Centro de Investigacion Biomedica EuroEspes   (Spain)

Author keywords

Amyloid precursor protein; Cerebrolysin; Neurodegeneration; Synapses; Water maze

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CEREBROLYSIN; NEUROTROPHIC FACTOR;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG WITHDRAWAL; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; MAZE TEST; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMINO ACIDS; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MAZE LEARNING; MEMORY; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS;

EID: 80052638741     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22712     Document Type: Article

References (67)

1. Alvarez XA, Lombardi VR, Corzo L, Perez P, Pichel V, Laredo M, Hernandez A, Freixeiro F, Sampedro C, Lorenzo R, Alcaraz M, Windisch M, Cacabelos R. 2000. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. J Neural Transm Suppl 59: 315-328.
2. Alvarez XA, Sampedro C, Perez P, Laredo M, Couceiro V, Hernandez A, Figueroa J, Varela M, Arias D, Corzo L, Zas R, Lombardi V, Fernandez-Novoa L, Pichel V, Cacabelos R, Windisch M, Aleixandre M, Moessler H. 2003. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol 18: 271-278.
3. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H. 2006. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 13: 43-54.
4. Alvarez XA, Sampedro C, Figueroa J, Tellado I, Gonzalez A, Garcia-Fantini M, Cacabelos R, Muresanu D, Moessler H. 2008. Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury. J Neural Transm 115: 683-692.
5. Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, Doppler E, Moessler H. 2011. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol 18: 59-68.
6. Chana G, Landau S, Beasley C, Everall IP, Cotter D. 2003. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry 53: 1086-1098.
7. + methamphetamine users. Neurology 67: 1486-1489.
8. Chen H, Tung YC, Li B, Iqbal K, Grundke-Iqbal I. 2007. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging 28: 1148-1162.
9. Chen KS, Gage FH. 1995. Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J Neurosci 15: 2819-2825.
10. Deigner HP, Haberkorn U, Kinscherf R. 2000. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin Invest Drugs 9: 747-764.
11. DeKosky ST, Scheff SW, Styren SD. 1996. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration 5: 417-421.
12. EBEWENeuroPharmaGmbH. 2009. Cerebrolysin® solution for injection: summary of product characteristics.
13. Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, Gage FH. 1987. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329: 65-68.
14. Francis-Turner L, Valouskova V. 1996. Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci Lett 202: 193-196.
15. Francis-Turner L, Valouskova V, Mokry J. 1996. The long-term effect of NGF, b-FGF and Cerebrolysin on the spatial memory after fimbria-fornix lesion in rats. J Neural Transm Suppl 47: 277.
16. Funke M, Fiehler J, Mewes I, Eiselt M, Rother I, Windisch M. 1998. Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia. J Neural Transm Suppl 53: 385-398.
17. Hefti F. 1986. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 6: 2155-2162.
18. Kromer LF. 1987. Nerve growth factor treatment after brain injury prevents neuronal death. Science 235: 214-216.
19. Levi-Montalcini R, Hamburger V. 1951. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 116: 321-361.
20. Mallory M, Honer W, Hsu L, Johnson R, Rockenstein E, Masliah E. 1999. In vitro synaptotrophic effects of Cerebrolysin in NT2N cells. Acta Neuropathol 97: 437-446.
21. Markowska AL, Koliatsos VE, Breckler SJ, Price DL, Olton DS. 1994. Human nerve growth factor improves spatial memory in aged but not in young rats. J Neurosci 14: 4815-4824.
22. Martinez-Serrano A, Fischer W, Soderstrom S, Ebendal T, Bjorklund A. 1996. Long-term functional recovery from age-induced spatial memory impairments by nerve growth factor gene transfer to the rat basal forebrain. Proc Natl Acad Sci U S A 93: 6355-6360.
23. Masliah E. 1995. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 10: 509-519.
24. Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W. 1999. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav 62: 239-245.
25. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DWJr, Morris JC. 2001. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56: 127-129.
26. Masliah E, Crews L, Hansen L. 2006. Synaptic remodeling during aging and in Alzheimer's disease. J Alzheimers Dis 9( Suppl 3): 91-99.
27. Maslow K. 2010. 2010 Alzheimer's disease facts and figures. Alzheimers Dement 6: 158-194.
28. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. 2000. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050-4058.
29. Mufson EJ, Conner JM, Kordower JH. 1995. Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. Neuroreport 6: 1063-1066.
30. Muresanu DF, Alvarez XA, Moessler H, Buia M, Stan A, Pintea D, Moldovan F, Popescu BO. 2008. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. J Neurol Sci 267: 112-119.
31. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH. 2009. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15: 331-337.
32. Onose G, Muresanu DF, Ciurea AV, Daia Chendreanu C, Mihaescu AS, Mardare DC, Andone I, Spanu A, Popescu C, Dumitrescu A, Popescu M, Grigorean V, Ungur B, Marinescu F, Colibbeanu I, Onose L, Haras M, Sandu A, Spircu T. 2009. Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin. J Med Life 2: 350-360.
33. Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E. 2010. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J 277: 3051-3067.
34. Plosker GL, Gauthier S. 2009. Cerebrolysin: a review of its use in dementia. Drugs Aging 26: 893-915.
35. Plosker GL, Gauthier S. 2010. Spotlight on cerebrolysin in dementia. CNS Drugs 24: 263-266.
36. Reinprecht I, Gschanes A, Windisch M, Fachbach G. 1999. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats. Histochem J 31: 395-401.
37. Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L. 1995. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem 270: 28257-28267.
38. Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. 2001. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res 66: 573-582.
39. Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, Moessler H, Masliah E. 2002. Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl 65: 327-336.
40. Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E. 2003a. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm 110: 1313-1327.
41. Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E. 2003b. The neuroprotective effects of Cerebrolysin trade mark in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm 110: 1313-1327.
42. Rockenstein E, Adame A, Mante M, Larrea G, Crews L, Windisch M, Moessler H, Masliah E. 2005a. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J Neural Transm 112: 269-282.
43. Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, Esposito L, Mucke L, Masliah E. 2005b. High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem 280: 32957-32967.
44. Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E. 2006. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res 83: 1252-1261.
45. Rockenstein E, Crews L, Masliah E. 2007a. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59: 1093-1102.
46. Rockenstein E, Mante M, Adame A, Crews L, Moessler H, Masliah E. 2007b. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease. Acta Neuropathol 113: 265-275.
47. Rockenstein E, Torrance M, Adame A, Mante M, Baron P, Rose JB, Crews L, Masliah E. 2007c. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27: 1981-1991.
48. Ruther E, Ritter R, Apecechea M, Freytag S, Windisch M. 1994. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27: 32-40.
49. Ruther E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch M. 2000. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm 107: 815-829.
50. Satou T, Itoh T, Tamai Y, Ohde H, Anderson AJ, Hashimoto S. 2000. Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks. J Neural Transm 107: 1253-1262.
51. Scheff S, DeKosky S, Price D. 1990. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 11: 29-37.
52. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA. 1995. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 15: 6213-6221.
53. Spencer B, Marr RA, Rockenstein E, Crews L, Adame A, Potkar R, Patrick C, Gage FH, Verma IM, Masliah E. 2008. Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. BMC Neurosci 9: 109.
54. Svendsen CN, Cooper JD, Sofroniew MV. 1991. Trophic factor effects on septal cholinergic neurons. Ann N Y Acad Sci 640: 91-94.
55. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. 1991. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580.
56. Trojanowski JQ, Shin RW, Schmidt ML, Lee VM. 1995. Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease. Neurobiol Aging 16: 335-340; discussion 341-335.
57. Tuszynski MH. 2007. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 21: 179-189.
58. Tuszynski MH, Gage FH. 1995. Bridging grafts and transient nerve growth factor infusions promote long-term central nervous system neuronal rescue and partial functional recovery. Proc Natl Acad Sci U S A 92: 4621-4625.
59. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J. 2005. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11: 551-555.
60. Ubhi K, Rockenstein E, Doppler E, Mante M, Adame A, Patrick C, Trejo M, Crews L, Paulino A, Moessler H, Masliah E. 2009. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Acta Neuropathol 117: 699-712.
61. Valouskova V, Francis-Turmer L. 1996. The short-term influence of b-FGF, NGF and Cerebrolysin on the memory impaired after fimbria-fornix lesion. J Neural Transm Suppl 47: 280.
62. Veinbergs I, Mante M, Mallory M, Masliah E. 2000. Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. J Neural Transm Suppl 59: 273-280.
63. Williams LR, Varon S, Peterson GM, Wictorin K, Fischer W, Bjorklund A, Gage FH. 1986. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A 83: 9231-9235.
64. Williams LR, Rylett RJ, Moises HC, Tang AH. 1991. Exogenous NGF affects cholinergic transmitter function and Y-maze behavior in aged Fischer 344 male rats. Can J Neurol Sci 18( Suppl 3): 403-407.
65. Windisch M, Gschanes A, Hutter-Paier B. 1998. Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J Neural Transm Suppl 53: 289-298.
66. 2+-dependent protease, calpain. J Neural Transm 107: 145-157.
67. Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, Lu M, Szalad A, Doppler E, Hitzl M, Zhang ZG. 2010. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 88: 3275-3281.